April 12th 2024
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Available Treatment Options for Patients With R/R MM
Elan Gorshein, DO, JD, MPH, explains his choice of frontline therapy for patients with relapsed/refractory multiple myeloma.
Optimizing Treatment Strategies in Relapsed/Refractory Multiple Myeloma
A panel of experts shares insight on treatment sequencing and selection in the setting of relapsed/refractory multiple myeloma.
Frontline Treatment Regimens in the Setting of Transplant-Ineligible NDMM
Experts from Ochsner Health highlight treatment options for patients who present with transplant-ineligible newly diagnosed multiple myeloma.
Curability, Maintenance Therapy, and Unmet Needs in Multiple Myeloma
A recent Satellite Sessions program hosted by CancerNetwork® brought together experts from different Ochsner Health campuses to discuss the diversity of practices among care providers regarding patient interactions and treatment choices.
Multiple Myeloma: Addressing Financial Barriers to Bispecifics
Key opinion leaders in multiple myeloma management address barriers inherent in the selection and use of bispecifics.
Bispecifics in MM: mSMART Guidelines for Monitoring and Managing AEs
Focused discussion on the mSMART guidelines for monitoring and managing adverse events associated with bispecific therapies in patients being treated for relapsed/refractory multiple myeloma.
Pharmacists’ Perspectives on Initiating Bispecific Therapy in Multiple Myeloma
Experts Scott A. Soefje, PharmD, and Kirollos S. Hanna, PharmD, share their perspectives on initial steps in initiating bispecific therapy for patients with multiple myeloma.
Insights from Experts at Mayo Clinic: Step-up and Treatment Dosing of Bispecifics
A panel of key opinion leaders from Mayo Clinic reflect on optimizing use of bispecifics in relapsed/refractory multiple myeloma, reviewing step-up dosing, administration, and followup strategies.
Treatment Approaches in Patients With Transplant-Ineligible NDMM
Noffar Bar, MD, discusses the MAIA study investigating a daratumumab combination therapy in patients with transplant-ineligible multiple myeloma.
Determining Transplant Ineligibility in Newly Diagnosed Multiple Myeloma
Focused discussion on factors that aid in determining transplant ineligibility when a patient presents with newly diagnosed multiple myeloma.
What is the Role of Transplant in Treating Patients With NDMM?
Key opinion leaders in multiple myeloma management reflect on the current role of stem cell transplant in patients with newly diagnosed disease.